Biogen outlines Apellis deal impacts with $120M-$130M 2026 other income headwind and non-GAAP EPS accretion in 2027
Source: SeekingAlpha
2026-04-29 14:23:24 ET
More on Biogen
- Biogen Inc. (BIIB) Q1 2026 Earnings Call Transcript
- Biogen Inc. 2026 Q1 - Results - Earnings Call Presentation
- Revisiting Eisai And Biogen's Leqembi Data For Alzheimer's Disease
- Biogen Non-GAAP EPS of $3.57 beats by $0.62, revenue of $2.48B beats by $230M
- Biogen trims full-year earnings outlook on BD impact
Read the full article on Seeking Alpha
For further details see:
Biogen outlines Apellis deal impacts with $120M-$130M 2026 other income headwind and non-GAAP EPS accretion in 2027
Biogen Inc.
NASDAQ: BIIB
BIIB Trading
-1.09% G/L:
$190.25 Last:
516,651 Volume:
$194.02 Open:
BIIB Latest News
BIIB Stock Data
$28,113,797,416
145,290,943
N/A
471
N/A
Pharmaceuticals
Healthcare
US
Cambridge
